Research ExplorerPublicationsLocal tumor control probability modeling of primary and seco...

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy

Standard

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. / Guckenberger, Matthias; Klement, Rainer J; Allgäuer, Michael; Andratschke, Nicolaus; Blanck, Oliver; Boda-Heggemann, Judit; Dieckmann, Karin; Duma, Marciana; Ernst, Iris; Ganswindt, Ute; Hass, Peter; Henkenberens, Christoph; Holy, Richard; Imhoff, Detlef; Kahl, Henning K; Krempien, Robert; Lohaus, Fabian; Nestle, Ursula; Nevinny-Stickel, Meinhard; Petersen, Cordula; Semrau, Sabine; Streblow, Jan; Wendt, Thomas G; Wittig, Andrea; Flentje, Michael; Sterzing, Florian.

In: RADIOTHER ONCOL, Vol. 118, No. 3, 03.2016, p. 485-91.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Guckenberger, M, Klement, RJ, Allgäuer, M, Andratschke, N, Blanck, O, Boda-Heggemann, J, Dieckmann, K, Duma, M, Ernst, I, Ganswindt, U, Hass, P, Henkenberens, C, Holy, R, Imhoff, D, Kahl, HK, Krempien, R, Lohaus, F, Nestle, U, Nevinny-Stickel, M, Petersen, C, Semrau, S, Streblow, J, Wendt, TG, Wittig, A, Flentje, M & Sterzing, F 2016, 'Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy', RADIOTHER ONCOL, vol. 118, no. 3, pp. 485-91. https://doi.org/10.1016/j.radonc.2015.09.008

APA

Guckenberger, M., Klement, R. J., Allgäuer, M., Andratschke, N., Blanck, O., Boda-Heggemann, J., Dieckmann, K., Duma, M., Ernst, I., Ganswindt, U., Hass, P., Henkenberens, C., Holy, R., Imhoff, D., Kahl, H. K., Krempien, R., Lohaus, F., Nestle, U., Nevinny-Stickel, M., ... Sterzing, F. (2016). Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. RADIOTHER ONCOL, 118(3), 485-91. https://doi.org/10.1016/j.radonc.2015.09.008

Vancouver

Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. RADIOTHER ONCOL. 2016 Mar;118(3):485-91. https://doi.org/10.1016/j.radonc.2015.09.008

Bibtex

@article{5f4bdb32b56e4811af17bcaf4c69f399,
title = "Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy",
abstract = "BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.RESULTS: After median follow-up of 19months and 16months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176Gy (151-223) and 160Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.",
author = "Matthias Guckenberger and Klement, {Rainer J} and Michael Allg{\"a}uer and Nicolaus Andratschke and Oliver Blanck and Judit Boda-Heggemann and Karin Dieckmann and Marciana Duma and Iris Ernst and Ute Ganswindt and Peter Hass and Christoph Henkenberens and Richard Holy and Detlef Imhoff and Kahl, {Henning K} and Robert Krempien and Fabian Lohaus and Ursula Nestle and Meinhard Nevinny-Stickel and Cordula Petersen and Sabine Semrau and Jan Streblow and Wendt, {Thomas G} and Andrea Wittig and Michael Flentje and Florian Sterzing",
note = "Copyright {\textcopyright} 2015 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = mar,
doi = "10.1016/j.radonc.2015.09.008",
language = "English",
volume = "118",
pages = "485--91",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy

AU - Guckenberger, Matthias

AU - Klement, Rainer J

AU - Allgäuer, Michael

AU - Andratschke, Nicolaus

AU - Blanck, Oliver

AU - Boda-Heggemann, Judit

AU - Dieckmann, Karin

AU - Duma, Marciana

AU - Ernst, Iris

AU - Ganswindt, Ute

AU - Hass, Peter

AU - Henkenberens, Christoph

AU - Holy, Richard

AU - Imhoff, Detlef

AU - Kahl, Henning K

AU - Krempien, Robert

AU - Lohaus, Fabian

AU - Nestle, Ursula

AU - Nevinny-Stickel, Meinhard

AU - Petersen, Cordula

AU - Semrau, Sabine

AU - Streblow, Jan

AU - Wendt, Thomas G

AU - Wittig, Andrea

AU - Flentje, Michael

AU - Sterzing, Florian

N1 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/3

Y1 - 2016/3

N2 - BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.RESULTS: After median follow-up of 19months and 16months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176Gy (151-223) and 160Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.

AB - BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.RESULTS: After median follow-up of 19months and 16months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176Gy (151-223) and 160Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.

U2 - 10.1016/j.radonc.2015.09.008

DO - 10.1016/j.radonc.2015.09.008

M3 - SCORING: Journal article

C2 - 26385265

VL - 118

SP - 485

EP - 491

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 3

ER -